CEO Kenneth Galbraith was paid $5,253,616 in fiscal year 2024, ↑ up 55.7% from fiscal year 2023, the 68th percentile of its disclosed peer group (SEC filing 0001193125-25-274338 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$5,253,616 ↑ Kenneth Galbraith total, FY2024 | 68th CEO pay percentile vs peers | 31:1 CEO-to-median pay ratio | 94.06% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
ZYME's next annual pay disclosure, estimated November 10, 2026.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kenneth Galbraith | $654,833 | $0 | $2,112,000 | $1,985,672 | $361,652 | $0 | $139,459 | $5,253,616 |
| Chief Executive Officer, President and Chair of Board of Directors | ||||||||
| Leone Patterson | 161,667 | 50,000 | 0 | 2,590,403 | 99,849 | 0 | 6,063 | 2,907,982 |
| Executive Vice President, Chief Business Officer and Chief Financial Officer | ||||||||
| Paul Moore | 494,683 | — | 633,600 | 595,702 | 214,102 | — | 48,716 | 1,986,803 |
| Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Kenneth Galbraith | $5,253,616 | $3,374,876 | $7,125,457 | ↑ +1,878,740 |
| Leone Patterson | 2,907,982 | — | — | — |
| Paul Moore | 1,986,803 | 1,682,237 | — | ↑ +304,566 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Zymeworks Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ZYME reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the Zymeworks Inc. Peer Teardown Report
$5,253,616 Kenneth Galbraith total, FY2024
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 9, 2026 · Source: 0001193125-25-274338 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for ZYME
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order ZYME
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses ZYME in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ZYME in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the Zymeworks Inc. Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2024 total |
|---|---|---|
| Alessandra Cesano | Independent Director | $810,227 |
| Carlos Campoy | Independent Director | $306,472 |
| Derek J. Miller | Independent Director | $301,472 |
| Hollings C. Renton | Former director (through FY2024) | $55,000 |
| Kelvin Neu | Independent Director | $296,472 |
| Kenneth Hillan | Former director (through FY2024) | $6,667 |
| Nancy Davidson | Independent Director | $294,972 |
| Neil Gallagher | Independent Director | $697,408 |
| Scott Platshon | Independent Director | — |
| Susan Mahony | Lead Independent Director | $314,597 |
| Troy M. Cox | Independent Director | $291,472 |
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Kenneth Galbraith | Director | 2025-12-22 | D | 100,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Galbraith | Director | 2025-12-22 | D | 47,528 | 27 | 1,284,311 | Common | Form 4 ↗ |
| Kenneth Galbraith | Director | 2025-12-22 | A | 100,000 | 0 | 0 | Common | Form 4 ↗ |
| Kenneth Galbraith | Director | 2026-01-05 | D | 22,657 | 25 | 568,620 | Common | Form 4 ↗ |
| Paul Moore | Chief Scientific Officer | 2026-01-05 | D | 10,821 | 25 | 271,574 | Common | Form 4 ↗ |
| Paul Moore | Chief Scientific Officer | 2026-01-05 | A | 20,000 | 0 | 0 | Common | Form 4 ↗ |
| Paul Moore | Chief Scientific Officer | 2026-01-05 | D | 9,289 | 25 | 233,125 | Common | Form 4 ↗ |
| Kenneth Galbraith | Director | 2026-01-05 | D | 31,686 | 25 | 795,220 | Common | Form 4 ↗ |
| Kenneth Galbraith | Director | 2026-01-05 | A | 47,668 | 0 | 0 | Common | Form 4 ↗ |
| Smith Jeffrey T L | EVP & Chief Medical Officer | 2026-01-05 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Smith Jeffrey T L | EVP & Chief Medical Officer | 2026-01-05 | D | 10,538 | 25 | 264,471 | Common | Form 4 ↗ |
| Smith Jeffrey T L | EVP & Chief Medical Officer | 2026-01-05 | A | 20,000 | 0 | 0 | Common | Form 4 ↗ |
| Paul Moore | Chief Scientific Officer | 2026-01-05 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Moore | Chief Scientific Officer | 2026-01-05 | D | 17,168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Moore | Chief Scientific Officer | 2026-01-05 | A | 17,168 | 0 | 0 | Common | Form 4 ↗ |
| Kenneth Galbraith | Director | 2026-01-05 | D | 66,666 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Galbraith | Director | 2026-01-05 | D | 47,668 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Galbraith | Director | 2026-01-05 | A | 66,666 | 0 | 0 | Common | Form 4 ↗ |
| Leone Patterson | EVP, Chief Bus & Fin Officer | 2026-01-06 | A | 459 | 11 | 4,842 | Common | Form 4 ↗ |
| Paul Moore | Chief Scientific Officer | 2026-01-12 | A | 66,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alessandra Cesano | Director | 2026-01-12 | A | 11,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kelvin Neu | Director | 2026-01-12 | A | 11,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregory A. Ciongoli | Director | 2026-01-12 | A | 11,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Smith Jeffrey T L | EVP & Chief Medical Officer | 2026-01-12 | D | 17,666 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Smith Jeffrey T L | EVP & Chief Medical Officer | 2026-01-12 | D | 9,310 | 23 | 211,090 | Common | Form 4 ↗ |
| Kelvin Neu | Director | 2026-01-12 | A | 7,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregory A. Ciongoli | Director | 2026-01-12 | A | 7,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Smith Jeffrey T L | EVP & Chief Medical Officer | 2026-01-12 | A | 17,666 | 0 | 0 | Common | Form 4 ↗ |
| Brian N. Cherry | Director | 2026-01-12 | A | 15,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Hollywood | EVP & Chief Operating Officer | 2026-01-12 | A | 66,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Hollywood | EVP & Chief Operating Officer | 2026-01-12 | D | 17,666 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Hollywood | EVP & Chief Operating Officer | 2026-01-12 | D | 6,120 | 23 | 138,762 | Common | Form 4 ↗ |
| Mark Hollywood | EVP & Chief Operating Officer | 2026-01-12 | A | 17,666 | 0 | 0 | Common | Form 4 ↗ |
| Kenneth Galbraith | Director | 2026-01-12 | A | 144,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Galbraith | Director | 2026-01-12 | A | 216,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Galbraith | Director | 2026-01-12 | D | 64,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Galbraith | Director | 2026-01-12 | D | 30,424 | 23 | 689,819 | Common | Form 4 ↗ |
| Kenneth Galbraith | Director | 2026-01-12 | A | 64,000 | 0 | 0 | Common | Form 4 ↗ |
| Paul Moore | Chief Scientific Officer | 2026-01-12 | A | 47,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Moore | Chief Scientific Officer | 2026-01-12 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Moore | Chief Scientific Officer | 2026-01-12 | D | 17,666 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Moore | Chief Scientific Officer | 2026-01-12 | D | 9,560 | 23 | 216,759 | Common | Form 4 ↗ |
| Paul Moore | Chief Scientific Officer | 2026-01-12 | A | 17,666 | 0 | 0 | Common | Form 4 ↗ |
| Susan Mahony | Director | 2026-01-12 | A | 7,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Susan Mahony | Director | 2026-01-12 | A | 11,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Carlos Campoy | Director | 2026-01-12 | A | 7,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alessandra Cesano | Director | 2026-01-12 | A | 7,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Galbraith | Director | 2026-01-12 | A | 222,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert E. Landry | Director | 2026-01-12 | A | 7,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert E. Landry | Director | 2026-01-12 | A | 11,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Carlos Campoy | Director | 2026-01-12 | A | 11,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian N. Cherry | Director | 2026-01-12 | A | 23,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Hollywood | EVP & Chief Operating Officer | 2026-01-12 | A | 47,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Hollywood | EVP & Chief Operating Officer | 2026-01-12 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kristin Stafford | EVP, Chief Financial Officer | 2026-04-06 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kristin Stafford | EVP, Chief Financial Officer | 2026-04-06 | A | 178,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kristin Stafford | EVP, Chief Financial Officer | 2026-04-06 | A | 119,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Platshon | EVP, Chief Business Officer | 2026-04-09 | A | 47,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Platshon | EVP, Chief Business Officer | 2026-04-09 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Schayowitz | See Remarks | 2026-04-09 | A | 76,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Schayowitz | See Remarks | 2026-04-09 | A | 47,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Platshon | EVP, Chief Business Officer | 2026-04-09 | A | 76,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Schayowitz | See Remarks | 2026-04-09 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul R. Schneider | EVP, General Counsel | 2026-05-13 | A | 178,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul R. Schneider | EVP, General Counsel | 2026-05-13 | A | 119,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Hollywood | EVP & Chief Operating Officer | 2026-07-06 | A | 939 | 22 | 20,865 | Common | Form 4 ↗ |
| Adam Schayowitz | EVP, Head of R&D | 2026-10-09 | D | 37,037 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Schayowitz | EVP, Head of R&D | 2026-10-09 | D | 13,832 | 26 | 357,557 | Common | Form 4 ↗ |
| Adam Schayowitz | EVP, Head of R&D | 2026-10-09 | A | 37,037 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Kenneth Galbraith | RSU | 2024-01-05 | — | — | 200,000 | — | $2,112,000 |
| Paul Moore | OPTION | 2024-01-05 | — | — | 90,000 | — | 595,702 |
| Kenneth Galbraith | OPTION | 2024-01-05 | — | — | 300,000 | — | 1,985,672 |
| Leone Patterson | OPTION | 2024-09-01 | — | — | 360,000 | — | 2,590,403 |
| Paul Moore | RSU | 2024-01-05 | — | — | 60,000 | — | 633,600 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Kenneth Galbraith | $2,112,000 | $0 | $1,985,672 | 0.0% |
| Paul Moore | 633,600 | 0 | 595,702 | 0.0% |
| Leone Patterson | 0 | 0 | 2,590,403 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Paul Moore | RSU | 34,334 | — | $502,650 |
| Kenneth Galbraith | Option | 107,500 | 8 | — |
| Paul Moore | Option | 38,750 | 8 | — |
| Kenneth Galbraith | RSU | 100,000 | — | 1,464,000 |
| Kenneth Galbraith | Option | 125,000 | 14.97 | — |
| Paul Moore | Option | 75,000 | 5.82 | — |
| Kenneth Galbraith | RSU | 200,000 | — | 2,928,000 |
| Paul Moore | Option | 90,000 | 10.56 | — |
| Kenneth Galbraith | Option | 300,000 | 10.56 | — |
| Kenneth Galbraith | RSU | 95,334 | — | 1,395,690 |
| Paul Moore | RSU | 60,000 | — | 878,400 |
| Leone Patterson | Option | 360,000 | 11.73 | — |
The goal of the compensation program is to attract, retain and motivate employees and executives by ensuring total compensation is competitive within the industry and supports overall strategy. The program aligns executive interests with stockholders through a mix of base salary, annual incentives, and long-term incentives tied to program development goals and key financial measurements.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-12-30 | 53,710,820 | 3,391,788 | 51,544 | 94.06% | Passed |
| 2024 | 2024-12-10 | 47,893,923 | 3,332,521 | 88,757 | 93.49% | Passed |
| 2023 | 2023-12-07 | 36,821,646 | 12,028,369 | 431,408 | 75.38% | Passed |
| 2022 | 2022-12-16 | 25,486,721 | 4,485,962 | 44,393 | 85.03% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-12-30 | 94.06%a |
| 2024 | 2024-12-10 | 93.49%b |
| 2023 | 2023-12-07 | 75.38%c |
a. Approved under the standard stated in the filing — “As a result, any shares not voted "FOR" a particular nominee (whether as a result of a stockholder abstention or a broker non-vote) will not be counted in such nominee's favor and will have no effect on the outcome of the election.* 2.”.
b. Approved under the standard stated in the filing — “As a result, any shares not voted FOR a particular nominee (whether as a result of a stockholder abstention or a broker non-vote) will not be counted in such nominees favor and will have no effect on the outcome of the election.* 2.”.
c. Approved under the standard stated in the filing — “As a result, any shares not voted FOR a particular nominee (whether as a result of a stockholder abstention or a broker non-vote) will not be counted in such nominees favor and will have no effect on the outcome of the election.* 2.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 31 : 1 |
|---|---|
| CEO total compensation | $5,110,637 |
| Median employee compensation | $164,072 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Alessandra CesanoIndependent · Nominating and Corporate Governance | $46,750 | — | $763,477 | — | $0 | $810,227 |
| Neil GallagherIndependent · Not standing for re-election | 35,125 | — | 662,283 | — | 0 | 697,408 |
| Susan MahonyIndependent · Lead Independent Director · Compensation (Chair) · Not standing for re-election | 73,125 | — | 241,472 | — | 0 | 314,597 |
| Carlos CampoyIndependent · Audit (Chair) | 65,000 | — | 241,472 | — | 0 | 306,472 |
| Derek J. MillerIndependent · Not standing for re-election | 60,000 | — | 241,472 | — | 0 | 301,472 |
| Kelvin NeuIndependent · Not standing for re-election | 55,000 | — | 241,472 | — | 0 | 296,472 |
| Nancy DavidsonIndependent · Not standing for re-election | 53,500 | — | 241,472 | — | 0 | 294,972 |
| Troy M. CoxIndependent · Not standing for re-election | 50,000 | — | 241,472 | — | 0 | 291,472 |
| Hollings C. RentonIndependent · Not standing for re-election | 55,000 | — | 0 | — | 0 | 55,000 |
| Kenneth HillanIndependent · Not standing for re-election | 6,667 | — | 0 | — | 0 | 6,667 |
| Scott PlatshonIndependent · Not standing for re-election | 0 | — | 0 | — | 0 | 0 |
| Kenneth GalbraithEmployee director · Board Chair · Not standing for re-election | — | — | — | — | — | 0 |
| Robert E. LandryIndependent · Audit · Compensation · Newly elected | — | — | — | — | — | — |
| Gregory A. CiongoliIndependent · Audit · Nominating and Corporate Governance (Chair) · Not standing for re-election · Newly elected | — | — | — | — | — | — |
| Oleg NodelmanIndependent · Compensation · Nominating and Corporate Governance · Not standing for re-election · Newly elected | — | — | — | — | — | — |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | The compensation committee subsequently recommended, and the Board of Directors approved, the adoption of stock ownership guidelines for non-management directors in August 2025 and September 2025, respectively, as further described in the section of this Proxy Statement entitled “Governance – Stock Ownership Guidelines”. |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $500,167 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $500,167 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Zymeworks Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Zymeworks Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cogent Biosciences | 2025 | Andrew Robbins | $724,554 | $12,993,250 | $13,447,680 | $561,600 | $27,762,684 |
| 2 | Bicycle Therapeutics | 2025 | Kevin Lee | 862,339 | 1,724,800 | 2,961,297 | 543,642 | 6,341,473 |
| 3 | AnaptysBio, Inc. | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 4 | Iteos Therapeutics | 2024 | Michel Detheux | 628,684 | 0 | 4,965,264 | 421,014 | 6,085,657 |
| 5 | NGM Biopharmaceuticals, Inc. | 2022 | David Woodhouse | 610,000 | 0 | 5,072,750 | 250,000 | 5,933,500 |
| 6 | Replimune Group, Inc. | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 7 | Xencor | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 8 | Zymeworks Inc. | 2024 | Kenneth Galbraith | 654,833 | 2,112,000 | 1,985,672 | 361,652 | 5,253,616 |
| 9 | Kura Oncology, Inc. | 2025 | Troy Wilson | 700,000 | 0 | 3,297,250 | 630,000 | 4,735,016 |
| 10 | Relay Therapeutics | 2025 | Sanjiv Patel | 707,846 | 0 | 3,513,900 | 424,708 | 4,646,454 |
| 11 | REGENXBIO Inc. | 2025 | Curran Simpson | 665,510 | 777,448 | 2,350,302 | 387,327 | 4,200,712 |
| 12 | Poseida Therapeutics, Inc. | 2023 | Mark Gergen | 611,667 | 1,442,285 | 1,413,936 | 336,420 | 3,818,018 |
| 13 | IGM Biosciences, Inc. | 2023 | Fred Schwarzer | 646,797 | 868,050 | 1,336,743 | 355,738 | 3,207,328 |
| 14 | C4 Therapeutics | 2025 | Andrew Hirsch | 694,925 | 710,730 | 848,007 | 573,313 | 2,940,975 |
| 15 | Repare Therapeutics Inc. | 2024 | Lloyd Segal | 630,500 | 278,000 | 1,203,960 | 242,743 | 2,368,837 |
| 16 | Gossamer Bio, Inc. | 2025 | Faheem Hasnain | 649,649 | 0 | 1,392,006 | 254,800 | 2,300,455 |
| 17 | Precision Biosciences | 2025 | Michael Amoroso | 650,875 | 1,025,086 | 0 | 0 | 2,189,467 |
| 18 | Adaptimmune Therapeutics plc | 2024 | Adrian Rawcliffe | 676,000 | 0 | 1,065,820 | 324,480 | 2,109,075 |
| 19 | MacroGenics, Inc. | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 20 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 21 | Sutro Biopharma, Inc. | 2025 | William Newell | 239,693 | 0 | 0 | 0 | 1,671,311 |
| 22 | Mersana Therapeutics, Inc. | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| 23 | Atara Biotherapeutics, Inc. | 2025 | AnhCo Nguyen | 668,800 | 0 | 0 | 0 | 1,068,069 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Zymeworks Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Aon plc |
| Adaptimmune Therapeutics plc | 80% | Options 75 · RSU 25 | not disclosed | Pearl Meyer |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| AnaptysBio, Inc. | 110% | not disclosed | No | Alpine Rewards |
| Atara Biotherapeutics, Inc. | not disclosed | RSU 100 | not disclosed | Pearl Meyer |
| Bicycle Therapeutics | 97% | not disclosed | not disclosed | not disclosed |
| C4 Therapeutics | 120% | not disclosed | not disclosed | Pearl Meyer |
| Cogent Biosciences | 135% | not disclosed | No | Compensia |
| Gossamer Bio, Inc. | 65% | not disclosed | No | Alpine Rewards |
| IGM Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Iteos Therapeutics | not disclosed | not disclosed | not disclosed | Radford |
| Kura Oncology, Inc. | 150% | not disclosed | No | Alpine Rewards |
| MacroGenics, Inc. | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Mersana Therapeutics, Inc. | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| NGM Biopharmaceuticals, Inc. | 75% | Option 100 | not disclosed | Aon |
| Poseida Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Precision Biosciences | 115% | RSU 100 | not disclosed | Aon |
| REGENXBIO Inc. | 97% | Options 75 · RSU 25 | not disclosed | Willis Towers Watson |
| Relay Therapeutics | 100% | Option 100 | not disclosed | Aon's Human Capital Solutions practice, a division of Aon plc |
| Repare Therapeutics Inc. | 70% | not disclosed | not disclosed | Aon |
| Replimune Group, Inc. | not disclosed | not disclosed | No | Pearl Meyer |
| Sutro Biopharma, Inc. | 115% | Options 59 · RSU 41 | not disclosed | FW Cook |
| Xencor | 110% | Options 60 · RSU 40 | not disclosed | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Kenneth Galbraith | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Summary Compensation Table”. As printed: 5,253,616. Filing ↗machine: r2 · c30 · span 541437–541446 |
| 2 | Section 01, Leone Patterson | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Summary Compensation Table”. As printed: 2,907,982. Filing ↗machine: r4 · c30 · span 546274–546283 |
| 3 | Section 01, Paul Moore | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Summary Compensation Table”. As printed: 1,986,803. Filing ↗ |
| 4 | Section 03, Kenneth Galbraith RSU | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t187 · r3 · c19 · span 519311–519320 |
| 5 | Section 03, Paul Moore OPTION | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t187 · r5 · c19 · span 522552–522559 |
| 6 | Section 03, Kenneth Galbraith OPTION | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t187 · r2 · c19 · span 517823–517832 |
| 7 | Section 03, Leone Patterson OPTION | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t187 · r4 · c19 · span 520922–520931 |
| 8 | Section 03, Paul Moore RSU | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t187 · r6 · c19 · span 524037–524044 |
| 9 | Section 07, pay ratio | DEF 14A | 2022-11-25 | 0001193125-22-292281 | Section “CEO Pay Ratio”. As printed: 31 : 1. Filing ↗ |
| 10 | Section 08, Alessandra Cesano | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Director Compensation”. As printed: 810,227. Filing ↗machine: span 785968–785975 |
| 11 | Section 08, Neil Gallagher | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Director Compensation”. As printed: 697,408. Filing ↗machine: span 790138–790145 |
| 12 | Section 08, Susan Mahony | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Director Compensation”. As printed: 314,597. Filing ↗machine: span 792952–792959 |
| 13 | Section 08, Carlos Campoy | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Director Compensation”. As printed: 306,472. Filing ↗machine: span 784572–784579 |
| 14 | Section 08, Derek J. Miller | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Director Compensation”. As printed: 301,472. Filing ↗machine: span 794403–794410 |
| 15 | Section 08, Kelvin Neu | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Director Compensation”. As printed: 296,472. Filing ↗machine: span 795817–795824 |
| 16 | Section 08, Nancy Davidson | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Director Compensation”. As printed: 294,972. Filing ↗machine: span 788720–788727 |
| 17 | Section 08, Troy M. Cox | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Director Compensation”. As printed: 291,472. Filing ↗machine: span 787327–787334 |
| 18 | Section 08, Hollings C. Renton | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Director Compensation”. As printed: 55,000. Filing ↗machine: span 797860–797866 |
| 19 | Section 08, Kenneth Hillan | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Director Compensation”. As printed: 6,667. Filing ↗machine: span 790736–790741 |
| 20 | Section 08, Scott Platshon | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 21 | Section 08, Kenneth Galbraith | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 22 | Section 08, Robert E. Landry | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 23 | Section 08, Gregory A. Ciongoli | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 24 | Section 08, Oleg Nodelman | DEF 14A | 2025-11-10 | 0001193125-25-274338 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 25 | Section 02, Kenneth Galbraith 2025-12-22 | Form 4 | 2025-12-22 | 0001193125-25-329028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Kenneth Galbraith 2025-12-22 | Form 4 | 2025-12-22 | 0001193125-25-329028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Kenneth Galbraith 2025-12-22 | Form 4 | 2025-12-22 | 0001193125-25-329028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Kenneth Galbraith 2026-01-05 | Form 4 | 2026-01-05 | 0001193125-26-003097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Paul Moore 2026-01-05 | Form 4 | 2026-01-05 | 0001193125-26-003095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Paul Moore 2026-01-05 | Form 4 | 2026-01-05 | 0001193125-26-003095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Paul Moore 2026-01-05 | Form 4 | 2026-01-05 | 0001193125-26-003095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Kenneth Galbraith 2026-01-05 | Form 4 | 2026-01-05 | 0001193125-26-003097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Kenneth Galbraith 2026-01-05 | Form 4 | 2026-01-05 | 0001193125-26-003097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Smith Jeffrey T L 2026-01-05 | Form 4 | 2026-01-05 | 0001193125-26-003102 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Smith Jeffrey T L 2026-01-05 | Form 4 | 2026-01-05 | 0001193125-26-003102 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Smith Jeffrey T L 2026-01-05 | Form 4 | 2026-01-05 | 0001193125-26-003102 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Paul Moore 2026-01-05 | Form 4 | 2026-01-05 | 0001193125-26-003095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Paul Moore 2026-01-05 | Form 4 | 2026-01-05 | 0001193125-26-003095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Paul Moore 2026-01-05 | Form 4 | 2026-01-05 | 0001193125-26-003095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Kenneth Galbraith 2026-01-05 | Form 4 | 2026-01-05 | 0001193125-26-003097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Kenneth Galbraith 2026-01-05 | Form 4 | 2026-01-05 | 0001193125-26-003097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Kenneth Galbraith 2026-01-05 | Form 4 | 2026-01-05 | 0001193125-26-003097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Leone Patterson 2026-01-06 | Form 4 | 2026-01-07 | 0001193125-26-006727 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Paul Moore 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010834 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Alessandra Cesano 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010856 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Kelvin Neu 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010860 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Gregory A. Ciongoli 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010864 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Smith Jeffrey T L 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010865 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Smith Jeffrey T L 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010865 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Kelvin Neu 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010860 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Gregory A. Ciongoli 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010864 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Smith Jeffrey T L 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010865 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Brian N. Cherry 2026-01-12 | Form 4 | 2026-01-13 | 0001193125-26-011793 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Mark Hollywood 2026-01-12 | Form 4 | 2026-01-13 | 0001193125-26-011885 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Mark Hollywood 2026-01-12 | Form 4 | 2026-01-13 | 0001193125-26-011885 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Mark Hollywood 2026-01-12 | Form 4 | 2026-01-13 | 0001193125-26-011885 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Mark Hollywood 2026-01-12 | Form 4 | 2026-01-13 | 0001193125-26-011885 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Kenneth Galbraith 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010790 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Kenneth Galbraith 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010790 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Kenneth Galbraith 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010790 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Kenneth Galbraith 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010790 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Kenneth Galbraith 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010790 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Paul Moore 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010834 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Paul Moore 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010834 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Paul Moore 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010834 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Paul Moore 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010834 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Paul Moore 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010834 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Susan Mahony 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010843 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Susan Mahony 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010843 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Carlos Campoy 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010852 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Alessandra Cesano 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010856 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Kenneth Galbraith 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010790 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Robert E. Landry 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010859 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Robert E. Landry 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010859 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Carlos Campoy 2026-01-12 | Form 4 | 2026-01-12 | 0001193125-26-010852 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Brian N. Cherry 2026-01-12 | Form 4 | 2026-01-13 | 0001193125-26-011793 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Mark Hollywood 2026-01-12 | Form 4 | 2026-01-13 | 0001193125-26-011885 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Mark Hollywood 2026-01-12 | Form 4 | 2026-01-13 | 0001193125-26-011885 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Kristin Stafford 2026-04-06 | Form 4 | 2026-04-07 | 0001193125-26-145305 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Kristin Stafford 2026-04-06 | Form 4 | 2026-04-07 | 0001193125-26-145305 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Kristin Stafford 2026-04-06 | Form 4 | 2026-04-07 | 0001193125-26-145305 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Scott Platshon 2026-04-09 | Form 4 | 2026-04-10 | 0001193125-26-151264 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Scott Platshon 2026-04-09 | Form 4 | 2026-04-10 | 0001193125-26-151264 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Adam Schayowitz 2026-04-09 | Form 4 | 2026-04-10 | 0001193125-26-151265 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Adam Schayowitz 2026-04-09 | Form 4 | 2026-04-10 | 0001193125-26-151265 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Scott Platshon 2026-04-09 | Form 4 | 2026-04-10 | 0001193125-26-151264 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Adam Schayowitz 2026-04-09 | Form 4 | 2026-04-10 | 0001193125-26-151265 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Paul R. Schneider 2026-05-13 | Form 4 | 2026-05-15 | 0001193125-26-227140 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Paul R. Schneider 2026-05-13 | Form 4 | 2026-05-15 | 0001193125-26-227140 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Mark Hollywood 2026-07-06 | Form 4 | 2026-07-06 | 0002104446-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Adam Schayowitz 2026-10-09 | Form 4 | 2026-10-09 | 0002127119-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Adam Schayowitz 2026-10-09 | Form 4 | 2026-10-09 | 0002127119-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Adam Schayowitz 2026-10-09 | Form 4 | 2026-10-09 | 0002127119-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 06, 2025 vote | Form 8-K | 2025-12-30 | 0001193125-25-337268 | Item 5.07 · say-on-pay result. As reported: 94.06% (votes for as printed: 53,710,820). Filing ↗ |
| 95 | Section 06, 2024 vote | Form 8-K | 2024-12-11 | 0001193125-24-275534 | Item 5.07 · say-on-pay result. As reported: 93.49% (votes for as printed: 47,893,923). Filing ↗ |
| 96 | Section 06, 2023 vote | Form 8-K | 2023-12-08 | 0001193125-23-291692 | Item 5.07 · say-on-pay result. As reported: 75.38% (votes for as printed: 36,821,646). Filing ↗ |
| 97 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 98 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 99 | Section 09b board cost (computed) | Computed | — | — | Cash 500,167 + equity 0 + all other 0 = 500,167, summed across the director compensation table rows.machine: formula: Σ = 500,167 |
| 100 | Cogent Biosciences, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173834 | CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. Filing ↗machine: r2 · c39 · span 369353–369363 |
| 101 | Bicycle Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001104659-26-046806 | CEO total compensation as printed in Bicycle Therapeutics's own proxy. As printed: 6,341,473. Filing ↗machine: t83 · r5 · c14 · span 491024–491033 |
| 102 | AnaptysBio, Inc., Section 10b CEO total | DEF 14A | 2026-06-29 | 0001193125-26-288408 | CEO total compensation as printed in AnaptysBio, Inc.'s own proxy. As printed: 6,133,943. Filing ↗machine: span 694406–694415 |
| 103 | Iteos Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-24 | 0000950170-25-057666 | CEO total compensation as printed in Iteos Therapeutics's own proxy. As printed: 6,085,657. Filing ↗machine: r2 · c27 · span 499272–499281 |
| 104 | NGM Biopharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2023-03-29 | 0001628280-23-009712 | CEO total compensation as printed in NGM Biopharmaceuticals, Inc.'s own proxy. As printed: 5,933,500. Filing ↗machine: r2 · c42 · span 406619–406628 |
| 105 | Replimune Group, Inc., Section 10b CEO total | DEF 14A | 2026-07-29 | 0001104659-26-087650 | CEO total compensation as printed in Replimune Group, Inc.'s own proxy. As printed: 5,845,982. Filing ↗machine: r1 · c41 · span 430765–430774 |
| 106 | Xencor, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001326732-26-000031 | CEO total compensation as printed in Xencor's own proxy. As printed: 5,521,205. Filing ↗machine: t32 · r3 · c19 · span 631325–631334 |
| 107 | Zymeworks Inc. (subject), Section 10b CEO total | DEF 14A | 2025-11-10 | 0001193125-25-274338 | CEO total compensation as printed in Zymeworks Inc.'s own proxy. As printed: 5,253,616. Filing ↗machine: r2 · c30 · span 541437–541446 |
| 108 | Kura Oncology, Inc., Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-151335 | CEO total compensation as printed in Kura Oncology, Inc.'s own proxy. As printed: 4,735,016. Filing ↗machine: span 1018180–1018189 |
| 109 | Relay Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186929 | CEO total compensation as printed in Relay Therapeutics's own proxy. As printed: 4,646,454. Filing ↗machine: r2 · c29 · span 660153–660162 |
| 110 | REGENXBIO Inc., Section 10b CEO total | DEF 14A | 2026-04-14 | 0001193125-26-155058 | CEO total compensation as printed in REGENXBIO Inc.'s own proxy. As printed: 4,200,712. Filing ↗machine: r2 · c16 · span 436444–436453 |
| 111 | Poseida Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2024-04-25 | 0000950170-24-048291 | CEO total compensation as printed in Poseida Therapeutics, Inc.'s own proxy. As printed: 3,818,018. Filing ↗machine: span 428155–428164 |
| 112 | IGM Biosciences, Inc., Section 10b CEO total | DEF 14A | 2024-04-26 | 0000950170-24-049091 | CEO total compensation as printed in IGM Biosciences, Inc.'s own proxy. As printed: 3,207,328. Filing ↗machine: r2 · c21 · span 824822–824831 |
| 113 | C4 Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028104 | CEO total compensation as printed in C4 Therapeutics's own proxy. As printed: 2,940,975. Filing ↗machine: span 511808–511817 |
| 114 | Repare Therapeutics Inc., Section 10b CEO total | DEF 14A | 2025-04-29 | 0001193125-25-103764 | CEO total compensation as printed in Repare Therapeutics Inc.'s own proxy. As printed: 2,368,837. Filing ↗machine: r2 · c29 · span 358846–358855 |
| 115 | Gossamer Bio, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001728117-26-000027 | CEO total compensation as printed in Gossamer Bio, Inc.'s own proxy. As printed: 2,300,455. Filing ↗machine: r2 · c48 · span 378559–378568 |
| 116 | Precision Biosciences, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001140361-26-013757 | CEO total compensation as printed in Precision Biosciences's own proxy. As printed: 2,189,467. Filing ↗machine: r2 · c19 · span 829996–830005 |
| 117 | Adaptimmune Therapeutics plc, Section 10b CEO total | DEF 14A | 2025-04-25 | 0001104659-25-039042 | CEO total compensation as printed in Adaptimmune Therapeutics plc's own proxy. As printed: 2,109,075. Filing ↗machine: r1 · c41 · span 814415–814424 |
| 118 | MacroGenics, Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001125345-26-000021 | CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. Filing ↗machine: r2 · c57 · span 494189–494198 |
| 119 | Alector, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 120 | Sutro Biopharma, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001193125-26-170354 | CEO total compensation as printed in Sutro Biopharma, Inc.'s own proxy. As printed: 1,671,311. Filing ↗machine: t15 · r6 · c29 · span 726958–726967 |
| 121 | Mersana Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-29 | 0001104659-25-040448 | CEO total compensation as printed in Mersana Therapeutics, Inc.'s own proxy. As printed: 1,613,754. Filing ↗machine: r1 · c41 · span 608188–608197 |
| 122 | Atara Biotherapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177285 | CEO total compensation as printed in Atara Biotherapeutics, Inc.'s own proxy. As printed: 1,068,069. Filing ↗machine: span 714260–714269 |
| 123 | Section 10a, Alector, Inc. reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector, Inc.'s most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
| 124 | Section 10a, AnaptysBio, Inc. reciprocity | DEF 14A | — | 0001193125-26-288408 | AnaptysBio, Inc.'s most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
| 125 | Section 10a, Atara Biotherapeutics, Inc. reciprocity | DEF 14A | — | 0000950170-25-059322 | Atara Biotherapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
| 126 | Section 10a, Bicycle Therapeutics reciprocity | DEF 14A | — | 0001558370-25-005258 | Bicycle Therapeutics's most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
| 127 | Section 10a, C4 Therapeutics reciprocity | DEF 14A | — | 0001628280-26-028104 | C4 Therapeutics's most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
| 128 | Section 10a, Gossamer Bio, Inc. reciprocity | DEF 14A | — | 0001728117-26-000027 | Gossamer Bio, Inc.'s most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
| 129 | Section 10a, MacroGenics, Inc. reciprocity | DEF 14A | — | 0001125345-26-000021 | MacroGenics, Inc. names Zymeworks Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 130 | Section 10a, NGM Biopharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-23-009712 | NGM Biopharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
| 131 | Section 10a, REGENXBIO Inc. reciprocity | DEF 14A | — | 0000950170-25-052069 | REGENXBIO Inc.'s most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
| 132 | Section 10a, Sutro Biopharma, Inc. reciprocity | DEF 14A | — | 0001193125-26-170354 | Sutro Biopharma, Inc. names Zymeworks Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 133 | Section 10a, Xencor reciprocity | DEF 14A | — | 0001326732-26-000031 | Xencor's most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
| 134 | Section 10a, Mersana Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-25-040448 | Mersana Therapeutics, Inc. names Zymeworks Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 135 | Section 10a, IGM Biosciences, Inc. reciprocity | DEF 14A | — | 0000950170-24-049091 | IGM Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
| 136 | Section 10a, Relay Therapeutics reciprocity | DEF 14A | — | 0001193125-26-186929 | Relay Therapeutics's most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
| 137 | Section 10a, Adaptimmune Therapeutics plc reciprocity | DEF 14A | — | 0001104659-25-039042 | Adaptimmune Therapeutics plc's most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
| 138 | Section 10a, Cogent Biosciences reciprocity | DEF 14A | — | 0001193125-26-173834 | Cogent Biosciences's most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
| 139 | Section 10a, Repare Therapeutics Inc. reciprocity | DEF 14A | — | 0001193125-25-103764 | Repare Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
| 140 | Section 10a, Precision Biosciences reciprocity | DEF 14A | — | 0001140361-26-013757 | Precision Biosciences's most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
| 141 | Section 10a, Kura Oncology, Inc. reciprocity | DEF 14A | — | 0001193125-26-151335 | Kura Oncology, Inc.'s most recent proxy was read; its disclosed peer group does not include Zymeworks Inc.. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the Zymeworks Inc. Executive Compensation Report
$1,500